Axovant Sciences Ltd to Post FY2018 Earnings of ($2.10) Per Share, Jefferies Group Forecasts (AXON)

Axovant Sciences Ltd (NASDAQ:AXON) – Research analysts at Jefferies Group dropped their FY2018 EPS estimates for shares of Axovant Sciences in a report issued on Monday. Jefferies Group analyst M. Yee now expects that the biotechnology company will post earnings per share of ($2.10) for the year, down from their prior estimate of ($1.80). Jefferies Group currently has a “Hold” rating and a $6.00 target price on the stock.

Several other analysts have also issued reports on AXON. Oppenheimer restated a “hold” rating on shares of Axovant Sciences in a research report on Tuesday. Cowen restated a “hold” rating on shares of Axovant Sciences in a research report on Tuesday. Zacks Investment Research lowered shares of Axovant Sciences from a “buy” rating to a “hold” rating in a research report on Wednesday. Chardan Capital upgraded shares of Axovant Sciences from a “sell” rating to a “neutral” rating and set a $2.50 price target on the stock in a research report on Wednesday, January 10th. Finally, ValuEngine upgraded shares of Axovant Sciences from a “strong sell” rating to a “sell” rating in a research report on Friday, February 2nd. Two investment analysts have rated the stock with a sell rating, eight have issued a hold rating and four have issued a buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus price target of $13.61.

Axovant Sciences (NASDAQ:AXON) traded up $0.05 during midday trading on Wednesday, reaching $1.68. 767,900 shares of the company’s stock traded hands, compared to its average volume of 2,125,557. The company has a quick ratio of 5.94, a current ratio of 4.58 and a debt-to-equity ratio of 0.45. The firm has a market cap of $185.92 and a price-to-earnings ratio of -0.73. Axovant Sciences has a 52 week low of $1.47 and a 52 week high of $27.98.

Several large investors have recently added to or reduced their stakes in the company. Wells Fargo & Company MN lifted its holdings in shares of Axovant Sciences by 1.6% during the 2nd quarter. Wells Fargo & Company MN now owns 22,790 shares of the biotechnology company’s stock worth $528,000 after acquiring an additional 355 shares during the period. The Manufacturers Life Insurance Company lifted its holdings in shares of Axovant Sciences by 16.6% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 22,377 shares of the biotechnology company’s stock worth $519,000 after acquiring an additional 3,184 shares during the period. California State Teachers Retirement System lifted its holdings in shares of Axovant Sciences by 10.0% during the 2nd quarter. California State Teachers Retirement System now owns 52,949 shares of the biotechnology company’s stock worth $1,228,000 after acquiring an additional 4,800 shares during the period. New York State Common Retirement Fund lifted its holdings in shares of Axovant Sciences by 27.5% during the 2nd quarter. New York State Common Retirement Fund now owns 32,000 shares of the biotechnology company’s stock worth $742,000 after acquiring an additional 6,899 shares during the period. Finally, Alliancebernstein L.P. lifted its holdings in shares of Axovant Sciences by 24.7% during the 2nd quarter. Alliancebernstein L.P. now owns 52,000 shares of the biotechnology company’s stock worth $1,206,000 after acquiring an additional 10,300 shares during the period. 96.82% of the stock is owned by institutional investors.

COPYRIGHT VIOLATION WARNING: This news story was originally reported by BBNS and is the sole property of of BBNS. If you are reading this news story on another site, it was copied illegally and reposted in violation of United States and international trademark and copyright laws. The correct version of this news story can be viewed at https://baseballnewssource.com/markets/axovant-sciences-ltd-to-post-fy2018-earnings-of-2-10-per-share-jefferies-group-forecasts-axon/1886425.html.

About Axovant Sciences

Axovant Sciences Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on acquiring, developing and commercializing therapeutics for the treatment of dementia, including Alzheimer’s disease and Lewy body dementia. The Company intends to develop a pipeline of product candidates to address the cognitive, functional and behavioral aspects of dementia and related neurological disorders.

Earnings History and Estimates for Axovant Sciences (NASDAQ:AXON)

Receive News & Ratings for Axovant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axovant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Three-Way Trade Sends Souza to Diamondbacks and Drury to Yankees
Three-Way Trade Sends Souza to Diamondbacks and Drury to Yankees
Eric Hosmer Agrees to Eight-Year Deal with San Diego Padres
Eric Hosmer Agrees to Eight-Year Deal with San Diego Padres
Report: Eduardo Nunez and Red Sox Agree to Deal for One Year
Report: Eduardo Nunez and Red Sox Agree to Deal for One Year
Los Angeles Angels Plan to Use Shohei Ohtani in Six-Man Rotation
Los Angeles Angels Plan to Use Shohei Ohtani in Six-Man Rotation
Cubs Sign Free Agent Yu Darvish
Cubs Sign Free Agent Yu Darvish
Mother of Pittsburgh Pirates Player Elias Diaz Has Been Kidnapped
Mother of Pittsburgh Pirates Player Elias Diaz Has Been Kidnapped


Leave a Reply

 
© 2006-2018 BBNS.